Toll-Interacting Protein in Resolving and Non-Resolving Inflammation
Innate leukocytes manifest dynamic and distinct inflammatory responses upon challenges with rising dosages of pathogen-associated molecular pattern molecules such as lipopolysaccharide (LPS). To differentiate signal strengths, innate leukocytes may utilize distinct intracellular signaling circuitrie...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2017.00511/full |
id |
doaj-5d49cf31549b4c3bbbc6d9353de9375c |
---|---|
record_format |
Article |
spelling |
doaj-5d49cf31549b4c3bbbc6d9353de9375c2020-11-24T22:38:59ZengFrontiers Media S.A.Frontiers in Immunology1664-32242017-05-01810.3389/fimmu.2017.00511268335Toll-Interacting Protein in Resolving and Non-Resolving InflammationElizabeth J. A. Kowalski0Liwu Li1Department of Biological Sciences, Virginia Polytechnic State University, Blacksburg, VA, USADepartment of Biological Sciences, Virginia Polytechnic State University, Blacksburg, VA, USAInnate leukocytes manifest dynamic and distinct inflammatory responses upon challenges with rising dosages of pathogen-associated molecular pattern molecules such as lipopolysaccharide (LPS). To differentiate signal strengths, innate leukocytes may utilize distinct intracellular signaling circuitries modulated by adaptor molecules. Toll-interacting protein (Tollip) is one of the critical adaptor molecules potentially playing key roles in modulating the dynamic adaptation of innate leukocytes to varying dosages of external stimulants. While Tollip may serve as a negative regulator of nuclear factor κ of activated B cells signaling pathway in cells challenged with higher dosages of LPS, it acts as a positive regulator for low-grade chronic inflammation in leukocytes programmed by subclinical low-dosages of LPS. This review aims to discuss recent progress in our understanding of complex innate leukocyte dynamics and its relevance in the pathogenesis of resolving versus non-resolving chronic inflammatory diseases.http://journal.frontiersin.org/article/10.3389/fimmu.2017.00511/fulllow-grade inflammationtoll-like receptor 4toll-interacting proteinlipopolysaccharidelysosome fusionmitochondria |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Elizabeth J. A. Kowalski Liwu Li |
spellingShingle |
Elizabeth J. A. Kowalski Liwu Li Toll-Interacting Protein in Resolving and Non-Resolving Inflammation Frontiers in Immunology low-grade inflammation toll-like receptor 4 toll-interacting protein lipopolysaccharide lysosome fusion mitochondria |
author_facet |
Elizabeth J. A. Kowalski Liwu Li |
author_sort |
Elizabeth J. A. Kowalski |
title |
Toll-Interacting Protein in Resolving and Non-Resolving Inflammation |
title_short |
Toll-Interacting Protein in Resolving and Non-Resolving Inflammation |
title_full |
Toll-Interacting Protein in Resolving and Non-Resolving Inflammation |
title_fullStr |
Toll-Interacting Protein in Resolving and Non-Resolving Inflammation |
title_full_unstemmed |
Toll-Interacting Protein in Resolving and Non-Resolving Inflammation |
title_sort |
toll-interacting protein in resolving and non-resolving inflammation |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2017-05-01 |
description |
Innate leukocytes manifest dynamic and distinct inflammatory responses upon challenges with rising dosages of pathogen-associated molecular pattern molecules such as lipopolysaccharide (LPS). To differentiate signal strengths, innate leukocytes may utilize distinct intracellular signaling circuitries modulated by adaptor molecules. Toll-interacting protein (Tollip) is one of the critical adaptor molecules potentially playing key roles in modulating the dynamic adaptation of innate leukocytes to varying dosages of external stimulants. While Tollip may serve as a negative regulator of nuclear factor κ of activated B cells signaling pathway in cells challenged with higher dosages of LPS, it acts as a positive regulator for low-grade chronic inflammation in leukocytes programmed by subclinical low-dosages of LPS. This review aims to discuss recent progress in our understanding of complex innate leukocyte dynamics and its relevance in the pathogenesis of resolving versus non-resolving chronic inflammatory diseases. |
topic |
low-grade inflammation toll-like receptor 4 toll-interacting protein lipopolysaccharide lysosome fusion mitochondria |
url |
http://journal.frontiersin.org/article/10.3389/fimmu.2017.00511/full |
work_keys_str_mv |
AT elizabethjakowalski tollinteractingproteininresolvingandnonresolvinginflammation AT liwuli tollinteractingproteininresolvingandnonresolvinginflammation |
_version_ |
1725710853187043328 |